Safe harbor for off label discussions between manufacturers and payers clears US House Energy & Commerce Health Subcommittee. Bill covers unapproved drugs as well as off label uses for approved agents.
Legislation allowing for communication between manufacturers and payers of clinical and economic information for unapproved drugs cleared the House Energy & Commerce Health Subcommittee Jan. 18, marking the first time a bill clearing the way for pre-approval information exchange has made it that far.
HR 2026, sponsored by Rep. Guthrie, R-Ky., now advances to the full Energy & Commerce Committee for consideration. It was...
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
